Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.

Ophthalmol Ther · 2026 · PMC13315027 · PMID 42141247

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combination therapy with a β-blocker plus a prostaglandin F2α receptor agonist showed a trend towards having the longest persistence duration, while β-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.